Novo Nordisk A/S (NVO)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from NVO's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Novo Nordisk A/S's 10-K filings. The deep dive has 15+ years, quarters and every line.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $140.8B | $177.0B | $232.3B | $290.4B | $309.1B |
| Net income | $47.8B | $55.5B | $83.7B | $101.0B | $102.4B |
| Free cash flow | $47.6B | $64.1B | $70.0B | $69.7B | $29.0B |
| EPS (diluted) | $10.37 | $12.22 | $18.62 | $22.63 | $23.03 |
| Operating margin | 41.7% | 42.3% | 44.2% | 44.2% | 41.3% |
Where the revenue comes from
Revenue by segments, fiscal 2025.
Superinvestors who own NVO
From each investor's latest 13F filing (what a 13F shows). 9 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Dodge & Cox Dodge & Cox |
Added | $978M | 0.51% | Q2 2026 |
| Tom Gayner Markel Group Inc. |
Held | $138M | 1.0% | Q2 2026 |
| Tom Steyer Farallon Capital Management LLC |
Added | $126M | 0.58% | Q2 2026 |
| Lee Ainslie Maverick Capital |
Trimmed | $79M | 0.70% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $16M | 0.00% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Added | $3M | 0.00% | Q2 2026 |
| Eric Marshall Hodges Capital Management |
New position | $2M | 0.16% | Q2 2026 |
| Murray Stahl Horizon Kinetics LLC |
Held | $735,879 | 0.01% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
New position | $228,099 | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Novo Nordisk A/S's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when NVO trades at or below it.
Free accounts get 3 price alerts. No card needed.
In the full deep dive
Questions
Are Novo Nordisk A/S insiders buying the stock?
No open-market insider purchases of NVO in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Novo Nordisk A/S?
9 of the superinvestors Investingly tracks hold NVO in their latest 13F, including Dodge & Cox, Tom Gayner, Tom Steyer.
Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.